Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Patrick Buchanan

Interventional Pain Medicine Camarillo, CA Medical Doctor

NPI 1275828568 CMS profile 1379436

1100 Paseo Camarillo, Camarillo, CA 93010

Open in the dashboard

General payments

$218,836

1,505 records reported · program years 2019–2025

Research payments

$9,890

Paid to them · 18 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$234,171 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Patrick Buchanan of Camarillo, CA is reported in the CMS Open Payments database as having received $218,836 across 1,505 general payments and $9,890 in research payments paid to them. Separately, studies naming them as principal investigator received $234,171 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $27,464 198
2024 General $48,201 255
2023 General $45,001 252
2023 Research $1,440 1
2022 General $56,756 283
2022 Research $3,030 7
2021 General $28,756 197
2021 Research $5,420 10
2020 General $3,691 130
2019 General $8,968 190

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Patrick Buchanan
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Patrick Buchanan were reported at $27,464. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Patrick Buchanan Interventional Pain Medicine median Middle half National median
2019 $8,968 $684 $216–$2,079 $163
2020 $3,691 $382 $122–$1,109 $114
2021 $28,756 $552 $167–$1,554 $132
2022 $56,756 $605 $187–$1,924 $149
2023 $45,001 $671 $195–$1,915 $160
2024 $48,201 $684 $206–$1,837 $164
2025 $27,464 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Painteq LLC $81,637 171 payments
  2. Saluda Medical Americas, Inc. $59,427 169 payments
  3. Abbott Laboratories $34,029 271 payments
  4. MML US, Inc. $9,008 17 payments
  5. Boston Scientific Corporation $6,461 84 payments
  6. Nevro Corp. $5,505 88 payments
  7. Medtronic, Inc. $3,983 59 payments
  8. BIOTRONIK NRO, Inc. $2,580 71 payments
  9. AbbVie, Inc. $2,020 97 payments
  10. SPR Therapeutics, Inc $1,536 19 payments
  11. Other $12,648 459 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $101,443 53 payments
  2. Food and Beverage $59,663 1,371 payments
  3. Education $30,643 16 payments
  4. Travel and Lodging $12,036 52 payments
  5. Compensation for serving as faculty or as a speaker for a medical education program $11,375 7 payments
  6. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $3,675 6 payments
Products named General payments · program years 2019–2025
  1. PAINTEQ $81,637 171 payments
  2. Evoke $39,644 112 payments
  3. Evoke SCS $19,784 57 payments
  4. PROCLAIM Neuromodulation $12,132 47 payments
  5. ReActiv8 $9,008 17 payments
  6. Proclaim IPG $6,231 58 payments
  7. PROCLAIM Neuromodulation $6,220 18 payments
  8. Proclaim Family of SCS IPGs $2,858 52 payments
  9. Senza Spinal Cord Stimulation System $2,834 36 payments
  10. IonicRF Generator $2,275 1 payment
  11. Other $37,483 1,041 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Painteq LLC $9,890 18 payments

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

2,766

Median for Pain Management: 951

Drug cost

$103,109

Median for Pain Management: $26,034

Branded share of claims

45%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ubrelvy Ubrogepant Brand 17 $23,263
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 828 $18,548
Botox Onabotulinumtoxina Brand 14 $18,424
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 273 $7,286
Gabapentin Generic 340 $6,343
Movantik Naloxegol Oxalate Brand 15 $5,943
Symproic Naldemedine Tosylate Brand 11 $4,914
Lidocaine Generic 39 $3,158
Naloxone Hcl Generic 62 $3,155
Pregabalin Generic 213 $2,042

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$156,066

Of which drugs: $4,940

Medicare patients

248

Average age 73

Services billed

2,388

160 women, 88 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 32%
Ischemic heart disease 28%
Diabetes 26%
Chronic kidney disease 21%
Osteoporosis 20%
Heart failure 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 30 166 $123

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
QULIPTA
$265 — —
BELBUCA
$213 — —
UBRELVY
$176 17 —
RELISTOR
$103 — —
VYEPTI
$78 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

1,523 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record